Bridgeway Capital Management’s Aclaris Therapeutics ACRS Stock Holding History

Bridgeway Capital Management’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$397K	Sell	75,019 -255,000	-77%	-$1.14M	0.01%	904
2026 Q1	$1.24M	Hold	330,019	–	–	0.02%	661
2025 Q4	$993K	Sell	330,019 -63,300	-16%	-$160K	0.02%	706
2025 Q3	$747K	Sell	393,319 -50,000	-11%	-$87.2K	0.02%	740
2025 Q2	$630K	Buy	443,319 +154,600	+54%	+$209K	0.01%	735
2025 Q1	$442K	Buy	288,719 +7,600	+3%	+$16.2K	0.01%	765
2024 Q4	$697K	Buy	281,119 +82,000	+41%	+$204K	0.02%	745
2024 Q3	$229K	Buy	199,119 +48,419	+32%	+$59.4K	0.01%	1034
2024 Q2	$166K	Buy	+150,700	New	+$177K	﹤0.01%	1090
2021 Q3	–	Sell	-135,000	Closed	-$2.37M	–	1284
2021 Q2	$2.37M	Sell	135,000 -79,300	-37%	-$1.8M	0.04%	558
2021 Q1	$5.4M	Sell	214,300 -25,100	-10%	-$491K	0.1%	274
2020 Q4	$1.55M	Sell	239,400 -35,000	-13%	-$148K	0.03%	611
2020 Q3	$705K	Hold	274,400	–	–	0.02%	781
2020 Q2	$445K	Buy	+274,400	New	+$368K	0.01%	893
2020 Q1	–	Sell	-87,500	Closed	-$165K	–	1270
2019 Q4	$165K	Hold	87,500	–	–	﹤0.01%	1217
2019 Q3	$95K	Hold	87,500	–	–	﹤0.01%	1248
2019 Q2	$192K	Buy	+87,500	New	+$477K	﹤0.01%	1189

Other funds holding ACRS

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Bridgeway Capital Management's ACRS Position: Q2 2026 in Review

Bridgeway Capital Management reduced its Aclaris Therapeutics (ACRS) stake by 77% in Q2 2026, selling an estimated $1.14M and leaving 75,019 shares worth $397K. The position accounts for 0.01% of the portfolio, ranked #904.

Bridgeway Capital Management first reported a position in ACRS in Q2 2019 and has held it in 17 quarters since. The position peaked at $5.4M in Q1 2021. 149 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

Bridgeway Capital Management held 75,019 shares of Aclaris Therapeutics worth $397K as of Q2 2026.
Bridgeway Capital Management sold 255,000 Aclaris Therapeutics shares in Q2 2026, an estimated $1.14M.
Aclaris Therapeutics made up 0.01% of Bridgeway Capital Management's portfolio in Q2 2026, its #904 holding.
Bridgeway Capital Management first reported a position in Aclaris Therapeutics in Q2 2019 and has held it in 17 quarters since.
Bridgeway Capital Management's Aclaris Therapeutics position peaked at $5.4M in Q1 2021.
149 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.